Inge Høgh Dufva

2.0k total citations
22 papers, 1.1k citations indexed

About

Inge Høgh Dufva is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Inge Høgh Dufva has authored 22 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 9 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Inge Høgh Dufva's work include Acute Myeloid Leukemia Research (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Inge Høgh Dufva is often cited by papers focused on Acute Myeloid Leukemia Research (11 papers), Acute Lymphoblastic Leukemia research (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Inge Høgh Dufva collaborates with scholars based in Denmark, United Kingdom and Sweden. Inge Høgh Dufva's co-authors include Claus Werenberg Marcher, Jan Maxwell Nørgaard, Marianne Tang Severinsen, Lene Sofie Granfeldt Østgård, Mette Nørgaard, Henrik Sengeløv, Lars Kjeldsen, Mette Klarskov Andersen, Keith Wheatley and Donald Milligan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Inge Høgh Dufva

20 papers receiving 1.1k citations

Peers

Inge Høgh Dufva

HEMAT

GENET

PHEOH

ONCOL

Sylvain Thépot France

Hervé Dombret France

Charlotte Guldborg Nyvold Denmark

Jana Březinová Czechia

Björn Rüter Germany

Mariadomenica Divona Italy

Hirotoshi Sakaguchi Japan

Sylvie Ramond France

JR Testa United States

Sélim Corm France

Sylvain Thépot France

Inge Høgh Dufva

1.0k ×1.2

HEMAT

542 ×1.3

408 ×1.3

GENET

214 ×0.8

PHEOH

200 ×0.8

ONCOL

Citations per year, relative to Inge Høgh Dufva Inge Høgh Dufva (= 1×) peers Sylvain Thépot

Countries citing papers authored by Inge Høgh Dufva

Since Specialization

Citations

This map shows the geographic impact of Inge Høgh Dufva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inge Høgh Dufva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inge Høgh Dufva more than expected).

Fields of papers citing papers by Inge Høgh Dufva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inge Høgh Dufva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inge Høgh Dufva. The network helps show where Inge Høgh Dufva may publish in the future.

Co-authorship network of co-authors of Inge Høgh Dufva

This figure shows the co-authorship network connecting the top 25 collaborators of Inge Høgh Dufva. A scholar is included among the top collaborators of Inge Høgh Dufva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inge Høgh Dufva. Inge Høgh Dufva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dufva, Inge Høgh, et al.. (2025). Early Specialized Palliative Care for Unresectable Pancreatic Cancer: A Quasi-Experimental Study. Journal of Pain and Symptom Management. 71(3). 419–428.

Dufva, Inge Høgh, Anne Ortved Gang, Lone Schejbel, et al.. (2021). Epigenetic therapy in combination with a multi-epitope cancer vaccine targeting shared tumor antigens for high-risk myelodysplastic syndrome - a phase I clinical trial. Cancer Immunology Immunotherapy. 71(2). 433–444. 10 indexed citations

Dufva, Inge Høgh, Anne Ortved Gang, Lone Schejbel, et al.. (2020). Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial. Blood. 136(Supplement 1). 23–24. 4 indexed citations

Gillberg, Linn, Andreas Due Ørskov, Ammar Nasif, et al.. (2019). Oral vitamin C supplementation to patients with myeloid cancer on azacitidine treatment: Normalization of plasma vitamin C induces epigenetic changes. Clinical Epigenetics. 11(1). 143–143. 58 indexed citations

Ørskov, Andreas Due, Sunil Kumar Saini, Anne-Mette Bjerregaard, et al.. (2017). Activation of T Cells Specific to Endogenous Retroviral Peptides: Possible Association with Clinical Response to Azacitidine in Myeloid Malignancies. Blood. 130. 4243–4243. 1 indexed citations

Østgård, Lene Sofie Granfeldt, Jan Maxwell Nørgaard, Klas Raaschou‐Jensen, et al.. (2016). The Danish National Acute Leukemia Registry. Clinical Epidemiology. Volume 8. 553–560. 26 indexed citations

Østgård, Lene Sofie Granfeldt, Bruno C. Medeiros, Henrik Sengeløv, et al.. (2015). Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study. Journal of Clinical Oncology. 33(31). 3641–3649. 279 indexed citations

Østgård, Lene Sofie Granfeldt, Jan Maxwell Nørgaard, Henrik Sengeløv, et al.. (2014). Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study. Leukemia. 29(3). 548–555. 52 indexed citations

Seymour, John F., D. W. Kim, Abebe Haregewoin, et al.. (2014). A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4(8). e238–e238. 56 indexed citations

10.

Gang, Anne Ortved, Thomas Mørch Frøsig, Marie K. Brimnes, et al.. (2014). 5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer Journal. 4(3). e197–e197. 65 indexed citations

11.

Tobiasson, Magnus, Mette Skov Holm, Mohsen Karimi, et al.. (2014). Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial. Blood Cancer Journal. 4(3). e189–e189. 44 indexed citations

12.

Nørgaard, Jan Maxwell, Lene Sofie Granfeldt Østgård, Eigil Kjeldsen, et al.. (2012). High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study. Blood. 120(21). 3542–3542.

13.

Möllgård, Lars, Leonie Saft, Marianne Bach Treppendahl, et al.. (2011). Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 96(7). 963–971. 43 indexed citations

14.

Tobiasson, Magnus, Ingunn Dybedal, Hege Garelius, et al.. (2011). Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,. Blood. 118(21). 3798–3798. 1 indexed citations

15.

Konar, Jan, et al.. (2010). Was the C282Y mutation an Irish Gaelic mutation that the Vikings helped disseminate?*. European Journal Of Haematology. 86(1). 75–82. 11 indexed citations

16.

Nicolini, Franck E., Wei Zhou, Giovanni Martinelli, et al.. (2009). Impact of Allogeneic Stem Cell Transplantation as Salvage Therapy After T315I Mutation Detection in Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients.. Blood. 114(22). 645–645. 3 indexed citations

17.

Nicolini, Franck E., Michael J. Mauro, Giovanni Martinelli, et al.. (2009). Epidemiologic study on survival of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. Blood. 114(26). 5271–5278. 100 indexed citations

18.

Nicolini, Franck E., Giovanni Martinelli, Dong‐Wook Kim, et al.. (2008). Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis. Blood. 112(11). 188–188. 1 indexed citations

19.

Stangegaard, Michael, Inge Høgh Dufva, & Martin Dufva. (2006). Reverse transcription using random pentadecamer primers increases yield and quality of resulting cDNA. BioTechniques. 40(5). 649–657. 71 indexed citations

20.

Ridell, Börje, Jan Carneskog, Hans Wedel, et al.. (2000). Incidence of chronic myeloproliferative disorders in the city of Göteborg, Sweden 1983–1992. European Journal Of Haematology. 65(4). 267–271. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact